Arrow image

09 Mar 2026

Strand’s Approach to Delivering Scalable, Clinical-Grade AI Infrastructure for Digital Histopathology

WRITTEN BY

Suhasini Singh

SHARE THIS

Blog

In many diseases, histopathology, which involves the microscopic examination of tissues and cells, is widely used for diagnosis, particularly in cancer. It plays a critical role in identifying, classifying, and characterizing different tissue types, cell populations, and disease states. Traditionally, this assessment relies on manual interpretation of H&E-stained slides, where pathologists examine tissue morphology based on their expertise and experience. While essential, manual analysis can be time-consuming and may show variability due to tissue complexity and differences in observer interpretation.

With the increasing digitization of histopathology images, computational methods are being explored to support analysis. Deep learning models can assist by automating image classification, helping improve consistency and enabling more scalable workflows. AI is increasingly being explored as a supportive tool in digital histopathology to augment diagnostic workflows.

However, applying AI in digital histopathology within real-world research and clinical environments depends on structured data pipelines, validation discipline, reproducibility, and governance. At Strand, we design and implement scalable, end-to-end AI workflows that transform fragmented imaging data into validated, interpretable, and deployable systems.

Infrastructure Supporting AI in Digital Histopathology

Our cloud-optimized infrastructure supports clinical-grade workflows while enabling interactive visualization, downloadable results, and real-time quality control dashboards.

 

What we offer:

  • Cloud-native pipelines
  • FAIR data structuring
  • Multi-modal integration
  • Experiment tracking
  • Reproducibility
  • Interpretability
  • Clinical-grade validation

 

 

Case Study: Breast Cancer Histopathology Classification

To demonstrate our approach in practice, we applied it to breast cancer histopathology classification. We used two widely recognized benchmark datasets:

  • BACH: dataset of 400 images across four classes at a fixed magnification
    • Image size 2048 x 1536 pixels
    • Magnification: 200x
  • BreakHis: dataset of 7,909 images from 82 patients, spanning multiple magnifications
    • Benign: 4 subclasses
    • Malignant: 4 subclasses
    • Image size: 700 X 460 pixels
    • Magnifications: 40x, 100x, 200x, 400x

Using both datasets enabled us to evaluate performance across structured and heterogeneous imaging environments.

In both datasets, combining two deep learning models improved performance compared to using a single model.

  • On BACH, Ensemble (ResNet50, VGG16)  accuracy reached 80.67%.
  • On BreakHis, accuracy reached 86.18%, with improved sensitivity across several subclasses.

All results were validated using cross-validation and reported with 95% confidence intervals to ensure reliability. This demonstrates not only model performance, but a reproducible and validated AI workflow capable of operating across datasets of varying complexity.

 

Results: BACH

Patch-wise Accuracy: We report the 95% confidence interval for the average accuracy across all 5 folds

 

Results: BreakHis

Image-wise Accuracy: We report the 95% confidence interval for the average accuracy across all 5 folds

 

The study is being extended to additional applications as ongoing projects, as shown in the table below:

If you are looking to implement scalable, governed AI workflows in digital histopathology or integrate imaging data into a unified architecture, you can reach out to us at [email protected].

References:

  1. Greeley C, Holder L, Nilsson EE, Skinner MK. Scalable deep learning artificial intelligence histopathology slide analysis and validation. Sci Rep. 2024.
  2. McCaffrey C, Jahangir C, Murphy C, Burke C, Gallagher WM, Rahman A. Artificial intelligence in digital histopathology for predicting patient prognosis and treatment efficacy in breast cancer. Expert Rev Mol Diagn. 2024.
  3. Mezei T, Kolcsár M, Joó A, Gurzu S. Image Analysis in Histopathology and Cytopathology: From Early Days to Current Perspectives. J Imaging. 2024.
  4. Tiwari A, Ghose A, Hasanova M, et al. The current landscape of artificial intelligence in computational histopathology for cancer diagnosis. Discov Oncol. 2025.

 

 

Today’s Pick
from Blogs

19 Jan 2026

TileDB and Strand Life Sciences: Solving Genomic Data Bottlenecks with Unified Data Architecture and AI Analytics

Chinta Sidharthan (Strand Life Sciences) and Devika Garg (TileDB)

Know More

15 Dec 2025

Modern Plant Genomics: Sequencing and Cloud-Driven Workflows

Suhasini Singh

Know More

Your Next
Blog Recommendations

13 Sep 2024

FDA Rule on Lab Developed Tests (LDTs)

3 | Partnering with New Molecular LDTs: Strand's FDA Compliance Roadmap

Divya Anantsri

Know More

13 Dec 2024

Strand’s Methylation Pipeline Series

1 | Strand’s Methylation Pipeline - An Overview - Part 1

Divya Anantsri

Know More

23 Sep 2024

New Frontiers in Cancer Therapy: Unveiling the Power of E3 Ligases and Protein Degradation Technologies

Suhasini Singh

Know More

Let's
Talk

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Form
About image
Please fill out this form to
download the case study.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.